You are here
CAMRAS VISION, INC.
UEI: CLLKJRDMUC49
# of Employees: 5
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Safety and Efficacy of a Titratable External Shunt
Amount: $886,057.00Glaucoma is a diverse group of chronic diseases that causes irreversible damage to the optic nerve and is a leading cause of blindness affectingmillion people worldwideIt is estimated thatinpeople who ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
SBIR Phase II: Adjustable Eye Pressure Control within an External Shunt
Amount: $713,172.00The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project allows for a more effective glaucoma treatment by adjusting eye pressure based on disease pro ...
SBIRPhase II2016National Science Foundation -
Safety and Efficacy of a Titratable External Shunt
Amount: $299,981.00Glaucoma is a diverse group of chronic diseases that causes irreversible damage to the optic nerve and is a leading cause of blindness affecting million people worldwide It is estimated that in people ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
SBIR Phase I:Feasibility of Adjustable Eye Pressure Control within an External Shunt
Amount: $150,000.00The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project allows for a more effective glaucoma treatment by tailoring eye pressure based on disease prog ...
SBIRPhase I2015National Science Foundation -
SBIR Phase I: Feasibility of The Use of a Debris Cartridge in an External Drainage Device
Amount: $149,978.00This Small Business Innovation Research Phase I project will demonstrate the feasibility of the use of a debris cartridge in an implant to prevent obstruction in debris-releasing glaucomas, such as uv ...
SBIRPhase I2013National Science Foundation -
External Glaucoma Drainage Device
Amount: $176,270.00DESCRIPTION (provided by applicant): Glaucoma is one of the leading causes of blindness in the world affecting 67 million people. Reduction of intraocular pressure (IOP) is the only proven treatment f ...
STTRPhase I2012Department of Health and Human Services National Institutes of Health